Literature DB >> 22703705

Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.

Baskar Nammalwar1, Richard A Bunce, K Darrell Berlin, Christina R Bourne, Philip C Bourne, Esther W Barrow, William W Barrow.   

Abstract

A series of substituted 2,4-diaminopyrimidines 1 has been prepared and evaluated for activity against Bacillus anthracis using previously reported (±)-3-{5-[(2,4-diamino-5-pyrimidinyl)methyl]-2,3-dimethoxyphenyl}-1-(1-propyl-2(1H)-phthalazinyl)-2-propen-1-one (1a), with a minimum inhibitory concentration (MIC) value of 1-3 μg/mL, as the standard. In the current work, the corresponding isobutenyl (1e) and phenyl (1h) derivatives displayed the most significant activity in terms of the lowest MICs with values of 0.5 μg/mL and 0.375-1.5 μg/mL, respectively. It is likely that the S isomers of 1 will bind the substrate-binding pocket of dihydrofolate reductase (DHFR) as in B. anthracis was found for (S)-1a. The final step in the convergent synthesis of target systems 1 from (±)-1-(1-substituted-2(1H)-phthalazinyl)-2-propen-1-ones 6 with 2,4-diamino-5-(5-iodo-3,4-dimethoxybenzyl)pyrimidine (13) was accomplished via a novel Heck coupling reaction under sealed-tube conditions.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22703705      PMCID: PMC3408765          DOI: 10.1016/j.ejmech.2012.05.018

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  22 in total

1.  Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.

Authors:  Xiaoming Li; Mark Hilgers; Mark Cunningham; Zhiyong Chen; Michael Trzoss; Junhu Zhang; Lucy Kohnen; Thanh Lam; Chris Creighton; Kedar G C; Kirk Nelson; Bryan Kwan; Mark Stidham; Vickie Brown-Driver; Karen J Shaw; John Finn
Journal:  Bioorg Med Chem Lett       Date:  2011-07-23       Impact factor: 2.823

2.  Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5'-(ω-carboxyalkoxy)benzyl]pyrido[2,3-d]pyrimidine derivatives.

Authors:  Vivian Cody; Jim Pace
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-12-16

3.  Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase.

Authors:  Kathleen M Frey; Michael N Lombardo; Dennis L Wright; Amy C Anderson
Journal:  J Struct Biol       Date:  2009-12-21       Impact factor: 2.867

4.  In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.

Authors:  Karen E Bowker; Patrick Caspers; Bérengère Gaucher; Alasdair P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

5.  Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships.

Authors:  Jennifer M Beierlein; Nanda G Karri; Amy C Anderson
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

6.  Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.

Authors:  C R Bourne; E W Barrow; R A Bunce; P C Bourne; K D Berlin; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

7.  Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.

Authors:  Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Patrick Caspers; Bérangère Gaucher; Gürkan Mert; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Authors:  Christina R Bourne; Richard A Bunce; Philip C Bourne; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

9.  In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs.

Authors:  Patrick Caspers; Luc Bury; Bérangère Gaucher; Jutta Heim; Stuart Shapiro; Sibylle Siegrist; Anne Schmitt-Hoffmann; Laure Thenoz; Heinrich Urwyler
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.

Authors:  Jennifer M Beierlein; Kathleen M Frey; David B Bolstad; Phillip M Pelphrey; Tammy M Joska; Adrienne E Smith; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

View more
  9 in total

1.  Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase.

Authors:  Christina R Bourne; Nancy Wakeham; Baskar Nammalwar; Vladimir Tseitin; Philip C Bourne; Esther W Barrow; Shankari Mylvaganam; Kal Ramnarayan; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Biochim Biophys Acta       Date:  2012-09-20

2.  Inhibition of bacterial dihydrofolate reductase by 6-alkyl-2,4-diaminopyrimidines.

Authors:  Baskar Nammalwar; Christina R Bourne; Richard A Bunce; Nancy Wakeham; Philip C Bourne; Kal Ramnarayan; Shankari Mylvaganam; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  ChemMedChem       Date:  2012-08-28       Impact factor: 3.466

3.  Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.

Authors:  Baskar Nammalwar; Christina R Bourne; Nancy Wakeham; Philip C Bourne; Esther W Barrow; N Prasad Muddala; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

4.  Comparative Study of the Frech Catalyst with Two Conventional Catalysts in the Heck Synthesis of 2,4-Diaminopyrimidine-based Antibiotics.

Authors:  Baskar Nammalwar; Richard A Bunce; K Darrell Berlin; Christina R Bourne; Philip C Bourne; Esther W Barrow; William W Barrow
Journal:  Org Prep Proced Int       Date:  2013       Impact factor: 1.628

5.  Evaluation of New Dihydrophthalazine-Appended 2,4-Diaminopyrimidines against Bacillus anthracis: Improved Syntheses Using a New Pincer Complex.

Authors:  Nagendra Prasad Muddala; Baskar Nammalwar; Subhashini Selvaraju; Christina R Bourne; Mary Henry; Richard A Bunce; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Molecules       Date:  2015-04-21       Impact factor: 4.411

6.  The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking.

Authors:  Christina R Bourne; Nancy Wakeham; Nicole Webb; Baskar Nammalwar; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Biochemistry       Date:  2014-02-11       Impact factor: 3.162

7.  Synthesis and biological evaluation of 2,4-diaminopyrimidine-based antifolate drugs against Bacillus anthracis.

Authors:  Baskar Nammalwar; N Prasad Muddala; Christina R Bourne; Mary Henry; Philip C Bourne; Richard A Bunce; Esther W Barrow; K Darrell Berlin; William W Barrow
Journal:  Molecules       Date:  2014-03-17       Impact factor: 4.411

8.  Sugar-based bactericides targeting phosphatidylethanolamine-enriched membranes.

Authors:  Catarina Dias; João P Pais; Rafael Nunes; Maria-Teresa Blázquez-Sánchez; Joaquim T Marquês; Andreia F Almeida; Patrícia Serra; Nuno M Xavier; Diogo Vila-Viçosa; Miguel Machuqueiro; Ana S Viana; Alice Martins; Maria S Santos; Ana Pelerito; Ricardo Dias; Rogério Tenreiro; Maria C Oliveira; Marialessandra Contino; Nicola A Colabufo; Rodrigo F M de Almeida; Amélia P Rauter
Journal:  Nat Commun       Date:  2018-11-19       Impact factor: 14.919

9.  Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant Staphylococcus aureus.

Authors:  Di Li; Rammohan R Yadav Bheemanaboina; Narsaiah Battini; Vijai Kumar Reddy Tangadanchu; Xian-Fu Fang; Cheng-He Zhou
Journal:  Medchemcomm       Date:  2018-08-01       Impact factor: 3.597

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.